All In MedTech

Device Trial Radar · NCT06100770

Aveir AR Coverage With Evidence Development (CED) Study

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

586

Planned (sponsor's estimate)

Start

Jan 18, 2024

Primary completion

Jan 2030

Study completion Jan 2031

Sponsor

Lead sponsor
Abbott Medical DevicesPublic (ABT)
Sponsor type
Industry
First posted
Oct 25, 2023

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this coverage with evidence development (CED) study is to evaluate complications and long-term health outcomes of the single-chamber Aveir Atrial Leadless Pacemaker device (aka Aveir™ AR LP system).

Conditions

  • Cardiac Pacemaker
  • Arrhythmia
  • Bradycardia

Interventions

  • Aveir AR Leadless PacemakerDevice

    This study will utilize real-world data from patients implanted with the Aveir AR Leadless Pacemaker. No device intervention is required in this study.

  • Single-chamber atrial transvenous pacemakerDevice

    This study will utilize real-world data from patients implanted with a single-chamber atrial transvenous pacemaker as a comparator to the Aveir AR LP study arm. No device intervention is required in this study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Acute device-related complication rateTime frame: 30 days
  2. Two-year survival rateTime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Abbott

    Sylmar, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.